Immunologic methods detect factor VIII (FVIII) antibodies in some inhibitor-negative specimens. Specimens were tested by modified Nijmegen-Bethesda assay (NBA) and fluorescence immunoassay. The NBA with preanalytical heat inactivation detects FVIII inhibitors down to 0.2 NBU. IgG 4 frequency validates the established threshold for positivity of ≥ 0.5 NBU for this NBA.
Introduction
The 'gold standard' assay for measurement of factor VIII inhibitors is the Nijmegen modification [1] of the Bethesda assay (BA) [2] , according to ISTH guidelines [3] . The Nijmegen-Bethesda assay (NBA) modified the reagents used in the BA, but maintained its method of calculation of the inhibitor units based on a ratio of the FVIII activity in a mixture of patient plasma and normal pooled plasma (NPP) to the FVIII activity in a control mixture, expressed as the percentage residual activity (RA). The original description of the BA in 1975 [2] recommended that quantification of positive inhibitors be carried out using percentage RA between 25% and 75%, corresponding to 0.4-2.0 Bethesda units (BU), and, more recently, it has been suggested that the limit of detection of the BA is 0.4 BU [4] . Although the graph provided by Kasper et al. [2] showed linearity to 100% RA, the authors recommended the use of 'more sensitive methods' for RA close to 100%, an assertion that is supported by several more recent studies using sensitive immunologic methods to detect FVIII antibodies in specimens found to be negative by the BA or the NBA [5] [6] [7] [8] [9] [10] . FVIII activity measurement methods have changed over the past 40 years, and documentation is lacking for the performance of the BA and NBA at low titers with today's automated methods for assigning FVIII activity levels. The ability to accurately measure inhibitors in the 0-0.4-Nijmegen-Bethesda units (NBU) range would allow for more precise monitoring of developing inhibitors. To this end, we have previously validated modifications to the NBA to free anti-FVIII antibodies bound to FVIII and increase its precision [11] , in order to minimize the number of false-negative results; and assay modifications to increase the sensitivity of the NBA have been proposed for use in monitoring of immune tolerance induction therapy (ITI) [12] . In this study, we examined the performance of the Centers for Disease Control and Prevention (CDC)-modified Nijmegen-Bethesda assay (CDC-NBA) at very low inhibitor titers in a single laboratory, and used measurement of anti-FVIII antibodies to validate the limit of detection and threshold for positivity.
Materials and methods
Specimens for FVIII inhibitor testing were collected from subjects with congenital hemophilia A enrolled in the Hemophilia Inhibitor Research Study between 2006 and 2012 at 17 US hemophilia treatment centers, as described in detail elsewhere [11, 13] . Healthy control subjects were paid donors with no history of coagulation disorder.
FVIII inhibitor measurements were performed with the CDC-NBA, as previously described [11] . Specimens were tested undiluted and at serial two-fold dilutions of 0.5, 0.25, 0.125, etc., in FVIII-deficient plasma (FVIIIDP; George King Biomedical, Overland Park, KS, USA) until a dilution with 100% RA was reached. Antibodies of the IgG 4 subclass binding to FVIII were measured by fluorescence immunoassay (FLI), as previously described [9] , in 382 specimens. The threshold for positivity for IgG 4 antibodies was set at two standard deviations (SD) above the mean for 56 healthy subjects [9] . Dilution curves were evaluated by linear regression with significance of deviation from 0 slope calculated with the F-test and linearity by runs test, with a significance level of P < 0.05. The limit of detection (LOD) of the assay was estimated with four methods. Method 1: with the classic method as described by the Clinical and Laboratory Standards Institute [14] , four blank specimens prepared from equal parts of NPP and FVIIIDP, and four low-level specimens of 1.0 NBU prepared by diluting high-titer inhibitor plasma (George King Biomedical) in imidazole buffer (Siemens, Marburg, Germany), were tested with two different lots of assay reagents over a period of 3 days with a total of 60 replicates of each type of specimen. Non-parametric methods were used to calculate limit of the blank (LOB) as the 95th percentile rank for negative specimens. The LOD was calculated as the LOB plus the SD of the low-level specimens corrected to the 95th percentile of the normal distribution. Method 2: the lowest dilution detected, i.e. having less than 100% RA (> 0 NBU), was calculated for 17 FVIII inhibitors of 1.0-24.6 NBU. Method 3: linear regression of the lower dilutions of 14 positive inhibitors with at least three dilutions between 50% and 100% RA, i.e. 1.1-1.7 NBU (n = 5), 6.7-9.6 NBU (n = 4), 13.1-14.9 NBU (n = 3), and 23.0-24.6 NBU (n = 2), was performed. The mean and SD of the NBU at which the regression line reached 100% RA and slope were calculated, and the LOD was calculated as 3SD/slope. Method 4: specimens from 30 healthy subjects were tested, and the LOD was calculated as mean + 3SD. Analyses were performed with GRAPHPAD PRISM 6.0 (GraphPad Software, San Diego, CA, USA).
Results and discussion
The CDC-NBA has been previously shown to have coefficients of variation (CVs) between runs of 9.8% (n = 117) for the negative control and of 10.3% (n = 114) for the 1.0-NBU positive control. Within-runs variation showed CVs of 5.3% (n = 10) for the negative control and of 4.8% (n = 10) for the positive control [11] . The CDC-NBA was performed on serial dilutions of high (13.1-24.6 NBU; Fig. 1A) , low (1.1-1.7 NBU; Fig. 1B ) and very low/negative (0.6 and 0.8 NBU/< 0.5 NBU; Fig. 1C ) specimens, in order to assess the assay's ability to measure inhibitors in specimens containing inhibitors approaching 100% RA. The linearity of each curve was verified by a runs test. All positive specimens showed linearity with a significant negative slope. Linearity between 100% and 75% RA suggests that NBU can be read below 0.4 NBU; however, the curves did not cross the y-axis at 100% RA, indicating that the LOD of this assay is not 0 NBU. As shown in Fig. 1C , very low positive specimens (0.6 and 0.8 NBU) showed a similar change with dilution, whereas negative specimens showed a consistent percentage RA when diluted and lacked a negative slope. Observation of multiple dilutions, even when not required by the assay protocol, may be useful in distinguishing very low titer inhibitors from negative specimens.
Calculation of the LOD, the lowest level at which inhibitor can be detected, with four standard methods is shown in Table 1 . All four statistical methods used indicated that the lower limit of detection of the CDC-NBA, which is reported to one decimal place, is 0.2 NBU. Similar calculations can be carried out by clinical laboratories on specimens prepared from assayed plasmas obtained commercially or from laboratories using validated methods.
Dardikh et al. developed a modified NBA that utilizes concentrated plasma in a chromogenic assay with a reported sensitivity of 0.03 NBU and reported that it detects low-titer inhibitors that remain after ITI and are responsible for a reduced FVIII half-life [12] . Such an assay may be superior to the NBA for this purpose; however, further studies using the FLI, which has a similar sensitivity [15] , for ITI monitoring are warranted.
A threshold for positivity of ≥ 0.5 NBU for the CDC-NBA was previously established on the basis of patient history in 674 subjects [11] ; its range can be estimated, on the basis of the CV of the CDC-NBA, to be 0.45-0.55. Because functional inhibitor titers have been shown to correlate most strongly with levels of anti-FVIII antibodies of the IgG 4 subclass [8,9,16-18], we measured anti-FVIII IgG 4 in specimens at various inhibitor titers (Fig. 2) . Among 64 specimens with ≥ 2.0 NBU, 62 (97%) showed the presence of anti-FVIII IgG 4 . Those with titers of 0.6-1.9 NBU had frequencies of 79-83%. At the CDC-NBA cutoff for positivity of 0.5 NBU, the IgG 4 frequency was 66.7%, decreasing to 14.3% at 0.4 NBU. IgG 4 antibodies were present in specimens with titers ≥ 0.2 NBU at rates above that seen in healthy controls [9] . These data confirm that a majority of specimens become antibody-positive at 0.5 NBU. Figure 2 also shows that specimens with 0.5-1.9 NBU have a lower frequency of IgG 4 positivity than higher-titer specimens, confirming the false-positive rate in that range previously reported with assays detecting both IgG and IgM antibodies [15] . IgG 4 anti-FVIII antibodies were absent in 19% of specimens with 0.5-1.9 NBU.
The presence of IgG 4 anti-FVIII antibodies in some specimens below the positive threshold confirms previous observations [5] [6] [7] [8] [9] [10] that some patients who are negative by the NBA have developed an antibody response to FVIII. In some cases, these antibodies appear to have clinical effects [7, 10] . A 9-year-old hemophilia A patient with titers of 0.4 NBU and 0.4 chromogenic Bethesda units, and strongly positive anti-FVIII antibodies, was observed to have FVIII recovery of 10% of expected and a half-life of 2 h postinfusion. ITI increased his recovery to 80% and his half-life to 6 h (M. J. Manco-Johnson, B. Boylan, C. H. Miller, unpublished observation). These observations and the finding that patients with titers of 0.5-1.9 NBU and those with higher titers have similar levels of anti-FVIII antibodies by FLI [19] suggest that in vitro measurement of inhibition may not always reflect the antibody load. In vitro conditions may not accurately mimic those present in vivo, where antibody affinity may play a role in determining the effect [20] . Diagnosis of an inhibitor in a hemophilic patient is a clinical judgement, and should not be included or excluded solely on the basis of a threshold for positivity.
These results show that the threshold for positivity with the CDC-NBA is slightly different from previous recommendations [3] based on the NBA without preanalytic heat inactivation, suggesting the need to re-evaluate the threshold for positivity when significant changes are made to the method. The FLI or another immunologic test may be useful as an objective measure for setting the threshold for a particular method. It has not been standard practice for each laboratory to set a reference range for FVIII inhibitors, and most laboratories lack sufficient specimens to do so. In order to use published definitions, however, published methods must be carefully followed, with any changes in procedure or substitution of reagents validated.
The CDC-NBA produces acceptable intralaboratory variability with the positive and negative controls recommended, which can be prepared from commercially available reagents [11] . Interlaboratory variability was not examined in this study. Interlaboratory variability of FVIII inhibitor results in external quality assessment programs is large, with CVs approaching 50% on distributed specimens and false-positive rates up to 32% [4, 21, 22] . This has been attributed to differences in laboratory methods and reagents. A study with 13 participants showed that a mean CV of 44% for six specimens with their original methods could be reduced to 8% by use of a standardized Nijmegen method and uniform reagents [22] , suggesting that adoption of a standard method on a national or an international level and the use of validated reagents could lead to improvement. Standardization has been limited by the lack of commercial availability of key reagents, such as imidazole-buffered NPP and controls, the cost of FVIII-deficient plasma, and the lack of an international standard.
The introduction of new, longer-acting treatment products has resulted in factor measurement issues, with differences related to the specific assay reagents used being noted [23] . Inhibitor assays using preanalytic heat inactivation avoid this issue, because the calculated NBU are based on a ratio of two FVIII activity readings measuring the FVIII activity of the added NPP and not patient or infused FVIII, which has been removed. If the two FVIII measurements used to calculate an inhibitor are carried out with appropriate quality control, using calibrators allowing reporting in international units, then, theoretically, differences in factor assay reagents and instruments should not affect the final NBU. This, however, remains to be demonstrated. The accuracy of the test will be dependent on the ability of the preanalytic heat inactivation step to remove any treatment product that may influence the results of the FVIII assays. This remains to be established with most significantly modified treatment products.
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